P C Lara
Overview
Explore the profile of P C Lara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
269
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgos-Burgos J, Vega V, Macias-Verde D, Vicente E, Murias C, Santana C, et al.
Clin Transl Oncol
. 2024 Dec;
PMID: 39718755
Aim: To assess for the first time the safety and feasibility of combining photon-IntraOperative RadioTherapy (ph-IORT) with hypofractionated whole-breast irradiation (hWBI) in patients referred to adjuvant radiotherapy after Breast-Conserving Surgery...
2.
Burgos-Burgos J, Vega V, Macias-Verde D, Vicente E, Murias C, Santana C, et al.
Clin Transl Oncol
. 2024 Oct;
PMID: 39466580
Aim: To assess for the first time the safety and feasibility of combining photon-intraoperative radiotherapy (ph-IORT) with hypofractionated whole breast irradiation (h-WBI) in patients referred to primary systemic therapy (PST)....
3.
Salas B, Ferrera-Alayon L, Espinosa-Lopez A, Vera-Rosas A, Salcedo E, Kannemann A, et al.
Clin Transl Radiat Oncol
. 2024 Mar;
45:100753.
PMID: 38433951
Background: Pancreatic Stereotactic Body Radiotherapy (SBRT) allows for the administration of a higher biologically effective doses (BED), that would be essential to achieve durable tumor control. Escalating treatment doses need...
4.
Vera-Rosas A, Aguiar D, Dominguez A, Cabrera-Vicente A, Martin-Barrientos P, Cabrera R, et al.
Clin Transl Radiat Oncol
. 2023 Apr;
40:100620.
PMID: 37066113
Background/purpose: The aim of this study is to assess for the first time the immediate and long term impact on quality-of-life of HBO treatments(HBOT) at 1.45 ATA (Absolute Atmospheric Pressure)...
5.
Tubin S, Vozenin M, Prezado Y, Durante M, Prise K, Lara P, et al.
Clin Transl Radiat Oncol
. 2023 Mar;
40:100605.
PMID: 36910025
•Improvement of therapeutic ratio by novel unconventional radiotherapy approaches.•Immunomodulation using high-dose spatially fractionated radiotherapy.•Boosting radiation anti-tumor effects by adding an immune-mediated cell killing.
6.
Burgos-Burgos J, Vega V, Macias-Verde D, Gomez V, Travieso-Aja M, Travieso J, et al.
Clin Transl Oncol
. 2021 Jun;
23(12):2579-2583.
PMID: 34091868
Introduction: Hypofractionated whole breast irradiation (hWBI) and intraoperative radiotherapy (IORT) could be associated in breast cancer patients showing high-risk factors of local recurrence after breast conserving therapy (BSC). The aim...
7.
LLoret M, Garcia-Cabrera L, Zajac M, Lara P
Clin Transl Oncol
. 2020 Aug;
23(1):190-194.
PMID: 32748093
Purpose: The aim of this study is to assess for the first time, the role of regional deep hyperthermia in combination with radiotherapy and systemic therapy in patients with poor...
8.
Burgos-Burgos J, Vega V, Macias-Verde D, Gomez V, Travieso-Aja M, Travieso J, et al.
Clin Transl Oncol
. 2020 May;
23(1):179-182.
PMID: 32445034
Introduction: Hypofractionated whole breast irradiation (HWBI) is the current standard of treatment after breast conservative surgery (BCS). Intraoperative radiotherapy (IORT) must be associated to WBI in patients showing high-risk factors...
9.
Horwich A, Babjuk M, Bellmunt J, Bruins H, de Reijke T, De Santis M, et al.
Ann Oncol
. 2019 Nov;
30(11):1697-1727.
PMID: 31740927
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary...
10.
Salas-Salas B, Dominguez-Nuez D, Cabrera R, Ferrera-Alayon L, LLoret M, Lara P
Clin Transl Oncol
. 2019 Jun;
22(1):151-157.
PMID: 31152306
Background: Definitive radiotherapy is an effective single-modality in T1 glottic cancer. Hypofractionated schemes could offer excellent results in a shorter treatment period. We aimed to evaluate the clinical outcomes and...